All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for EMERGENT BIOSOLUTIONS · Pharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Maryland · House · Senate · $40,000.00 income · posted Apr 18, 2025

Official filing document

Bills named in this filing 1

HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

Lobbying activity 3

Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2025. Opioid and heroin addiction legislation, naloxone access and awareness.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26, Opioid crisis legislation, naloxone access and awareness, FY2026 NDAA provisions related to biological and chemical defense and access to naloxone, H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025

Defense

National Defense Authorization Act for FY2025, provisions related to biological and chemical defense and access to naloxone.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.